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Abstract
Background: Application of cardiac stem cells combined with biomaterial scaffold is a promising therapeutic
strategy for heart repair after myocardial infarction. However, the optimal cell types and biomaterials remain elusive.
Methods: In this study, we seeded Isl1+ embryonic cardiac progenitor cells (CPCs) into decellularized porcine
small intestinal submucosa extracellular matrix (SIS-ECM) to assess the therapeutic potential of Isl1+ CPCs and the
biocompatibility of SIS-ECM with these cells.
Results: We observed that SIS-ECM supported the viability and attachment of Isl1+ CPCs. Importantly, Isl1+ CPCs
differentiated into cardiomyocytes and endothelial cells 7 days after seeding into SIS-ECM. In addition, SIS-ECM with
CPC-derived cardiomyocytes showed spontaneous contraction and responded to β-adrenergic stimulation. Next,
patches of SIS-ECM seeded with CPCs for 7 days were transplanted onto the outer surface of infarcted myocardium
in mice. Four weeks after transplantation, the patches were tightly attached to the surface of the host myocardium
and remained viable. Transplantation of patches improved cardiac function, decreased the left ventricular
myocardial scarring area, and reduced fibrosis and heart failure.
Conclusions: Transplantation of Isl1+ CPCs seeded in SIS-ECM represents an effective approach for cell-based
heart therapy.
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Background
Myocardial infarction (MI) is among the leading causes
of death globally. In the United States, the overall preva-
lence of MI is 3.0% among adults older than age 20
years, and MI caused over 1.1 million deaths in 2014 [1].
Although many patients survive acute MI, most of them
subsequently develop heart failure, which likely results
from left ventricular (LV) remodeling. Previous studies
have confirmed that ischemic cardiomyocyte death, myo-
cardial fibrosis, and inflammation are characteristic patho-
logical features of cardiac remodeling after MI [2, 3].
Cardiomyocyte loss after MI has long been considered
irreversible, with the heart lacking sufficient regenerative
capacity [4–6].
Heart transplantation is the only curative treatment
for heart failure, but is subject to significant limitations,
such as lack of available donors and problems with im-
mune rejection or infection [7]. Stem cell-based therapies
have been proposed as a potential strategy to promote re-
generation of the injured myocardium. Previous studies
had shown that cells were lost rapidly after direct injection
into the myocardium, intracoronary injection, or intraven-
ous injection [8–13]. A promising alternative strategy has
been to use biomaterials to provide an adequate three-
dimensional scaffold for transplanted cells, thereby in-
creasing cell viability and even producing better cardiac
tissue models in vivo [14, 15]. Various types of cells have
been combined with different materials for cardiac repair
and generation of new myocardium, including induced
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pluripotent stem cells, cardiomyocytes (CMs), and cardiac
progenitor cells (CPCs) [16–18]. Bone marrow stem cells
promote angiogenesis and modulate inflammation in a
paracrine fashion, but cannot directly achieve the regener-
ation of functional myocardium [19–21]. Many studies
have shown that CMs are the ideal cell type for produc-
tion of cardiac tissue, but it is very difficult to isolate hu-
man CMs for clinical application. Therefore, CMs derived
from pluripotent stem cells could be the most feasible cell
source for generation of cardiac tissue in combination
with biomaterials, but purified CMs cannot form vascu-
larized tissue or grafts when seeded into biomaterials.
In contrast, embryonic CPCs can be differentiated
from embryonic stem/induced pluripotent cells and then
manipulated to undergo differentiation into various
types of cardiac cells, including CMs, vascular endothe-
lial cells, and smooth muscle cells. Therefore, CPCs
could be the ideal cell source for engineering of vascu-
larized tissues or grafts [22, 23]. Embryonic CPCs can be
identified by a specific marker (Isl1) and have been iso-
lated from the second heart field [24, 25]. As bona-fide
cardiac progenitors, Isl1+ CPCs may be a more suitable
cell source for cardiac tissue engineering and heart re-
generation [26–32].
Decellularized porcine small intestinal submucosa
extracellular matrix (SIS-ECM) is a xenogeneic bio-
degradable scaffold with properties that allows its use as
a biomaterial [33, 34]. Several studies have demonstrated
that SIS-ECM promotes tissue repair in regenerative
applications such as wound healing [33, 35, 36]. SIS-
ECM can serve as a scaffold that provides adequate
three-dimensional support for transplanted cells, po-
tentially sustaining cell survival and promoting prolifer-
ation [33, 37]. In addition, it does not trigger an
antigenic response and can induce regeneration of na-
tive tissue after transplantation in vivo [38]. Therefore,
in this study we aim to determine the therapeutic po-
tential of Isl1+ CPCs seeded in SIS-ECM to repair MI
heart.
Methods
Culture, differentiation, and characterization of cells
Mouse embryonic stem cells (ES) were cultured according
to the protocol reported previously and differentiation
into CPCs was performed according to a previously
published protocol with some modifications [39]. In
brief, mES cells were digested with TrypLE (Invitrogen)
and suspended in differentiation medium 1 (DM1:
IMDM supplemented with Ham’s F12, bovine serum al-
bumin, B27, N2 (Invitrogen), monothioglycerol, and
vitamin C (Sigma-Aldrich)) at a density of 75,000 cells/ml
for culture in a Petri dish for 48 hours. The embryoid
bodies (EBs) that formed were then harvested, dissociated,
and cultured in DM1 supplemented with 5 ng/ml
VEGF, 5 ng/ml Activin A, and 0.8 ng/ml BMP4 (R&D
Systems, Minneapolis, MN, USA) at a density of
100,000 cells/ml in a Petri dish for 40 hours. The EBs
were collected again, dissociated, and cultured in 0.1%
gelatin-coated cell culture dishes in differentiation
medium 2 (DM2: StemPro-34 SFM supplemented with
vitamin C, glutamine (Invitrogen), monothioglycerol
(Sigma-Aldrich), 5 ng/ml VEGF, 10 ng/ml bFGF, and 25
ng/ml FGF10 (R&D Systems)) for 32 hours to generate
Isl1+ CPCs. The Isl1+ CPCs were collected and seeded
in SIS-ECM or culture plate, and then cultured in DM2
medium without growth factors (no VEGF, bFGF, or
FGF10) for 7-day differentiation. The cells were charac-
terized by immunofluorescence staining using the stand-
ard protocol. Fluorescence images were obtained with an
Olympus BX53 fluorescence microscope (Olympus
Corporation, Tokyo, Japan).
Assessment of the biocompatibility of SIS-ECM with
Isl1+ CPCs
Porcine SIS-ECM was kindly donated by CorMatrix
Cardiovascular, Inc. (Atlanta, GA, USA). Isl1+ CPCs
were prestained with Dil (Invitrogen) and were seeded
directly into 24-well plates or into SIS-ECM before culture
in DM2. The cell density in SIS-ECM was 1.0 × 105/mm3.
Fluorescence images were captured at 24 hours after
seeding, and then cck8 reagent (Dojindo Molecular
Technologies, Rockville, MD, USA) was added to the wells
and culture was continued for another 2 hours. An aliquot
(200 μl) of culture medium was transferred to a 96-well
plate and the absorbance was measured at 450 nm using a
microplate reader. After 24 hours of culture, some of the
SIS-ECM/cell constructs were fixed overnight at 4 °C with
2.5% phosphate-buffered glutaraldehyde (Sigma-Aldrich),
and post-fixed for 1 hour with 1% osmium tetroxide
(Sigma-Aldrich). The samples were then rinsed three
times with PBS, dehydrated through a graded ethanol
series, and dried using hexamethyldisilazane (Sigma-
Aldrich). Processed SIS-ECM/cell constructs were cut
open at the center, sputter-coated with gold, and im-
aged at 10 kV using a Philips XL30 FEG scanning elec-
tron microscope (Philips, the Netherlands) to detect
cell adhesion. On days 1 and 7 of culture, SIS-ECM/
cell constructs were fixed with 4% paraformaldehyde
for 10 min, and then were placed in 5% sucrose-PBS
for 1 hour and in 15% sucrose-PBS for another 1 hour.
Specimens were embedded in CRYO-OCT Compound
(Andwin Scientific, Tryon, NC, USA), frozen at –20 °C,
and cut into 10-μm sections. Cells in the SIS-ECM/cell
constructs were stained by DAPI (1:10,000) at 24 hours
after seeding. On day 7, the differentiated cells in culture
plates and frozen sections of SIS-ECM/cell constructs
were fixed with 4% paraformaldehyde for immunofluores-
cence staining by the standard protocol.
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Animal models
This study was approved by the Committee for Animal
Research of the University of Michigan and was per-
formed in accordance with the recommendations of the
American Association for the Accreditation of Laboratory
Animal Care.
Induction of MI and transplantation of SIS-ECM patches
seeded with Isl1+ CPCs
MI was induced in nude (NU-Foxn1nu) mice (Charles
River Laboratories, Wilmington, MA, USA) by permanent
ligation of the left anterior descending coronary artery
(LAD). Then 3.6 mm3 of SIS-ECM (depth 3 mm, width 3
mm, height 0.4 mm) was seeded with 3.6 × 105 Isl1+ CPCs
and incubated in DM2 medium without growth factors
for 7 days before transplantation. Fibrin gel (EVICEL®
Fibrin Sealant (Human); Ethicon, Somerville, MA, USA)
was applied to the edges of SIS-ECM patches containing
Isl1+ CPC-differentiated cardiac cells with DM2 medium
for attachment of the patches to the infarcted region of
the left ventricle after induction of MI or to the left ven-
tricle of normal hearts.
Histological analyses
Histological studies were performed by standard proto-
cols. Briefly, mice were sacrificed and their hearts were
perfused with 20% KCl, fixed with zinc fixative solution
(BD Pharmingen), and dehydrated with 30% sucrose.
After embedding in paraffin, the samples were sectioned
and processed for Masson’s trichrome staining. Images
were captured with an Aperio (Leica Biosystems, Buffalo
Grove, IL, USA) and infarct size was measured using
Image J software.
Real-time polymerase chain reaction analysis
Total RNA was extracted from cells in culture plates,
cells in SIS-ECM, or the left ventricles of mice using an
RNAeasy Mini kit (Qiagen, Valencia, CA, USA), and 1
μg of total RNA was converted to cDNA with reverse
transcriptase in a 10-μl reaction mixture. We tested the
products of each RT reaction by regular PCR to confirm
reverse transcription. Real-time PCR was carried out
with a SYBR Green PCR Master Mix kit (Invitrogen,
Carlsbad, CA, USA) and the 7300 Sequence Detection
system (ABI).
Echocardiography
Echocardiography was performed at 28 days after MI
using a Vevo 770 system (Visualsonic, Toronto, Canada).
Using M-mode tracings, the following parameters were
measured by an investigator blinded to the treatment of
the mice: the LV ejection fraction (EF), cardiac output,
end-diastolic volume, and LV end-diastolic and end-
systolic dimensions (LVEDD and LVESD, respectively).
In addition, LV fractional shortening (LVFS) was calcu-
lated according to the following equation:
LVFS ¼ LVEDD – LVESDð Þ=LVEDD½   100:
Statistical analysis
Results are presented as the mean ± SD. Data were ana-
lyzed by one-way analysis of variance followed by
Fisher’s least significant difference test. Differences were
considered significant at p < 0.05.
Results
Isl1+ CPCs were easily attached to and proliferated
normally in SIS-ECM
Isl1+ CPCs were obtained as described previously.
Differentiation of mES cells was induced by a pub-
lished EB-based cardiac differentiation protocol with
minor modifications. Isl1+ CPCs were identified by
immunofluorescence staining (Fig. 1a, b). Proliferation
Isl1+ CPCs (Additional file 1: Figure S1) were har-
vested and seeded into the SIS-ECM patches (Fig. 1c, d)
at 1.0 × 105 cells/mm3. In order to investigate whether the
patches supported cell survival, viable Isl1+ CPCs pre-
stained with Dil (Invitrogen) were observed by bright-field
and fluorescence microscopy (Fig. 1e, f ) at 24 hours after
seeding. DAPI staining of frozen sections also showed
that Isl1+ CPCs remained viable in SIS-ECM patches
(Fig. 1g, h). To investigate attachment of Isl1+ CPCs to
the SIS-ECM patch material, patches were seeded with
Isl1+ CPCs and scanning electron microscopy was per-
formed, revealing that CPCs spread over and became
attached to the patches (Fig. 1i). In addition, the
proliferation rate of CPCs in SIS-ECM and in culture
plates (control) was compared by the Cell Counting
Kit-8 (CCK-8) assay, revealing no significant difference
of proliferation between SIS-ECM and control culture
(Fig. 1j). In contrast, as a control, we found that it was
more challenging to seed ESC-derived CMs into SIS-
ECM patches, which could be partially due to the rela-
tively larger size and irregularity of the cell shape of the
CMs.
Isl1+ CPCs differentiated into CMs and endothelial cells in
SIS-ECM
To evaluate the multilineage differentiation potential of
Isl1+ CPCs, we investigated the transition of cells
seeded into the SIS-ECM from CPCs to CMs and endo-
thelial cells. Immunofluorescence revealed differenti-
ation of Isl1+ CPCs into CMs (α-actinin-positive and
cTnT-positive cells; Fig. 2b, d) and endothelial cells
(CD31-positive cells; Fig. 2e) at 7 days after seeding
into SIS-ECM or culture plates (Fig. 2a, c, e). Real-time
PCR showed that there were no significant differences
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of α-actinin, cTnT, and CD31 mRNA expression in
cells between SIS-ECM and control culture.
Isl1+ CPCs seeded in SIS-ECM formed a multilayered cardiac
tissue-like structure and responded to β-adrenergic
stimulation
HE-stained cross-sections of SIS-ECM showed a multi-
layered structure (Fig. 3a), and indicated that a multilayered
cardiac tissue-like cell sheet (Fig. 3b) was generated by
seeding Isl1+ CPCs into SIS-ECM. To investigate the re-
sponse of the cardiac tissue-like cell sheet to β-adrenergic
stimulation, 10 μM isoproterenol was added to the culture
medium, resulting in a reversible significant increase in the
frequency of contraction (Fig. 3c).
Transplantation of SIS-ECM patches seeded with CPCs
reduced myocardial scarring after MI
The formation of beating multilayered tissue-like struc-
tures in SIS-ECM after seeding with CPCs prompted us
to examine the patch’s function in heart repair in vivo.
SIS-ECM was seeded with Isl1+ CPCs and cultured in
Fig. 1 Isl1+ CPCs remain viable and attach to the extracellular matrix
of the patch material (SIS-ECM). a, b Isl1+ CPCs. c Extracellular
matrix (SIS-ECM) patch material. d Scanning electron micrograph
of SIS-ECM. e, f Viable Isl1+ CPCs prestained by Dil in SIS-ECM
obtained by bright-field (e) and fluorescence (f) microscopy. g, h Images
of frozen sections of Isl1+ CPCs seeded into SIS-ECM obtained by
bright-field (g) and fluorescence microscopy (h). i Scanning electron
microscopy shows attachment of Isl1+ CPCs (arrowhead) in SIS-
ECM. j CPC proliferation rate in SIS-ECM compared to standard
culture (control) measured using the Cell Counting Kit-8 (CCK-8)
assay. SIS small intestinal submucosa
Fig. 2 Isl1+ CPCs differentiate into CMs and endothelial cells after
seeding into SIS-ECM. a, c Isl1+ CPC-derived CMs (α-actinin-positive
and cTnT-positive) in culture obtained by fluorescence microscopy.
b, d Isl1+ CPC-derived CMs (α-actinin-positive and cTnT-positive) in
SIS-ECM obtained by fluorescence microscopy. e Isl1+ CPC-derived
endothelial cells (CD31+) in culture obtained by fluorescence microscopy.
f Isl1+ CPC-derived endothelial cells (CD31+) in SIS-ECM obtained by
fluorescence microscopy. g Relative quantitative RNA expression of
α-actinin, cTnT, and CD31 by CPC-derived CMs or endothelial cells
growing in SIS-ECM compared to standard culture plates. SIS small
intestinal submucosa
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vitro for 7 days before transplantation. Nude mice
(Charles River Laboratories, Wilmington, MA, USA)
were used to generate MI by permanent ligation of the
left anterior descending coronary artery (LAD); immedi-
ately after MI, SIS-ECM and SIS-ECM-CPC patches
were transplanted to the surface area of infarcted region
of the left ventricle. Gel was applied to the edges of SIS-
ECM patches to improve attachment of the patches to
the hearts. Mice were euthanized on day 28 after trans-
plantation and the hearts were harvested for histological
analysis. As shown in Fig. 4, transplantation of SIS-ECM
or SIS-ECM-CPC to healthy mice did not affect the
heart morphology (Fig. 4, b, compare c to d and e).
Transplantation of SIS-ECM to MI heart appeared to
have modest effect on reducing the scar area (Fig. 4, b,
compare g to f; p = 0.061). In contrast, SIS-ECM with
CPC seeding significantly reduced the scar area com-
pared with the MI group (Fig. 4, b, compare h to f; p =
0.003). This indicated that transplantation of SIS-ECM
patches seeded with CPCs maximally reduced infarct
size after MI.
Transplantation of SIS-ECM patches with CPCs improved
cardiac function after MI
Echocardiographic examination was performed 28
days after transplantation of SIS-ECM-CPCs. There
were no significant differences among the Sham +
Patch, Sham + Patch + Cell, and Sham groups (Fig. 5,
a, c, g, h), suggesting that cell-seeded patch implant-
ation did not affect the function of normal hearts. In
mice with MI, echocardiography showed a significant de-
crease of LVEF (33.48 ± 6.36%) and LVFS (18.88 ± 3.81%)
and a significant increase of LVEDD (4.74 ± 0.34%) and
LVESD (3.99 ± 0.38%) compared with Sham mice (Fig. 5,
a, d, g–j). Transplantation of the patch alone increased the
LVEF modestly in MI mice (Fig. 5, d, e, g). In contrast,
transplantation of Patch + Cell significantly increased the
LVEF (62.16 ± 8.96%) and LVFS (32.44 ± 6.54%) and de-
creased the LVEDD (3.41 ± 0.35%) and LVESD (2.32% ±
0.38%) compared with the MI only mice (Fig. 5, d, f, g–j).
These findings suggested that implantation of SIS-ECM
Fig. 3 Structure of SIS-ECM seeded with CPCs for 1 week and response to β-adrenergic stimulation. a, b Cross-sectional images (HE staining) of
SIS-ECM (a) and SIS-ECM seeded with CPCs after 1 week (b). c Contraction rate of SIS-ECM seeded with CPCs before and after the addition of
10 μM isoproterenol on day 8 of culture. Data expressed as mean ± SD. n = 5. *p < 0.05 vs basal state. SIS small intestinal submucosa
Fig. 4 Implantation of SIS-ECM seeded with CPCs reduced myocardial
scarring. Schematic view showing attachment of SIS-ECM-CPC patch to
the heart with fibrin gel (a). Percent area of myocardial scarring in mice
with MI. Data are mean ± SD obtained from Masson’s trichrome slides
(b). Data expressed as mean ± SD. n = 6. *p = 0.003 vs MI mice.
Representative images of mouse hearts (Masson’s trichrome staining)
for Sham group (c), Sham + Patch group (d), Sham+ Patch + Cell
group (e), MI group (f), MI + Patch group (g), and MI + Patch + Cell
group (h). LV left ventricular, MI myocardial infarction, SIS small
intestinal submucosa
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Fig. 5 (See legend on next page.)
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seeded with CPC-derived CMs could be an effective strat-
egy to ameliorate LV dysfunction with heart failure after
MI.
Transplantation of SIS-ECM-CPC patches reduced BNP,
ANP, Collagen I, Collagen III, and TGF-β mRNA expression
in the LV myocardium after MI
Real-time quantitative PCR analysis indicated that ex-
pression of BNP, ANP, Collagen I, Collagen III, and
TGF-β mRNA was increased in the LV myocardium of
mice with MI-induced heart failure compared with sham
mice mice (Fig. 6a–e). Consistent with our echocardiog-
raphy findings, implantation of SIS-ECM seeded with
CPC-derived CMs reduced BNP, ANP, Collagen I, Colla-
gen III, and TGF-β mRNA expression in the LV myocar-
dium (Fig. 6a–e). These data demonstrate that the
transplantation of SIS-ECM-CPC significantly prevented
heart failure, improved cardiac function, and reduced
myocardial fibrosis in mice after MI.
Discussion
In this study, we investigated whether transplantation of
SIS-ECM seeded with Isl1+ CPCs could improve cardiac
function and alleviate myocardial damage after MI. To
generate a high yield of Isl1+ CPCs from mES cells, we
employed modified EB-based differentiation based on
previous protocols [39]. In order to determine whether
Isl1+ CPCs could survive in SIS-ECM and attach to the
biomaterial, we first investigated the viability and at-
tachment of Isl1+ CPCs 24 hours after seeding into
SIS-ECM. The findings suggested that SIS-ECM pro-
vide a suitable environment for growth and act as a
(See figure on previous page.)
Fig. 5 Implantation of SIS-ECM-CPC improved cardiac function in mice with MI. Representative M-mode echocardiographic images obtained in
Sham (a), Sham + Patch (b), Sham + Patch + Cell (c), MI control (d), MI + Patch (e), and MI + Patch + Cell (f) groups. Quantitative cardiac function
analysis of LVEF (g), LVFS (h), LVEDD (i), and LVESD (j) 4 weeks after permanent LAD occlusion of the six groups. Data expressed as mean ± SD.
n = 6. MI + Patch + Cell vs sham mice, *p < 0.001; MI + Patch + Cell vs MI mice, #p < 0.004. Modest or no statistical significance was detected
between MI + Patch and MI groups. n = 6. MI + Patch vs MI mice, LVEF, #p = 0.034. LVEF left ventricular ejection fraction, LVFS left ventricular
fractional shortening, MI myocardial infarction
Fig. 6 Implantation of SIS-ECM-CPC reduced myocardial BNP, ANP, Collagen I, Collagen III, and TGF-β mRNA expression in mice with MI. a BNP, b
ANP, c Collagen I, d Collagen III, and e TGF-β mRNAs were detected by real-time PCR using cDNAs obtained from the whole LV myocardium of sham
mice, MI mice, MI + Patch mice, and MI + Patch + Cell mice, and expression was normalized for that of GAPDH. Data expressed as mean ± SD. n = 6.
*p < 0.05 vs sham mice, #p < 0.05 vs MI mice. MI myocardial infarction
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scaffold for Isl1+ CPCs. We compared differentiation of
Isl1+ CPCs into CMs and endothelial cells in SIS-ECM
with differentiation under normal culture conditions. Our
data indicated no significant differences in the differenti-
ation of CMs and endothelial cells between SIS-ECM and
standard culture. This suggested that Isl1+ CPCs could ef-
fectively differentiate into CMs and endothelial cells after
seeding into SIS-ECM, allowing utilization for engineering
of vascularized cardiac tissue and cardiac tissue regener-
ation (Figs. 1, 2, and 3).
In the present study, CPCs were seeded into por-
cine SIS-ECM, and 7 days after seeding we could ob-
serve the alignment of CPC-derived CMs along the
longitudinal axis of the SIS fibers. In addition, we ob-
served the spontaneous contraction of SIS-ECM
seeded with CPC-derived CMs. The contraction rate
of the SIS-ECM/CPC-derived CM constructs was sig-
nificantly increased by short-term β-adrenergic stimu-
lation with isoproterenol. These findings suggested
the formation of a functional patch with contractile
activity of CMs.
We believe that our studies represent significant pro-
gress compared to a previous study in which a myocar-
dial patch was generated [40]. In the previous study,
neonatal rat CMs were seeded to decellularized por-
cine SIS to form CM sheets adjacent to the SIS layers
[40]. The SIS-ECM-CM patch can beat in a somewhat
nonsynchronous contraction pattern and preserve
heart function after transplantation. However, it is very
difficult to isolate human CMs for clinical applications
and the seeding of CMs appears very challenging. In
particular, it is very inefficient for CM cells to be
seeded inside the SIS-ECM. In contrast, embryonic
Isl1+ CPCs are much easier to be seeded into SIS-
ECM. In our studies, we generated a functional spon-
taneous contracting patch by seeding Isl1+ CPCs into
porcine SIS-ECM. Our studies suggest an attractive al-
ternative cell source (human ISL1+ CPCs) in future
clinical studies.
The major finding of the present study was that
transplantation of SIS-ECM-CPCs showed consider-
able therapeutic potential. To avoid secondary damage,
SIS-ECM-CPC patches were attached to the outer sur-
face of the infarcted region of the heart using fibrin gel
instead of sutures (Fig. 4a). The cells at the surface of
the SIS-ECM-CPC patches were in direct contact with
the outer surface of the infarcted myocardium after
implantation. Four weeks post implantation, the
patches were found to be tightly attached to the sur-
face of the host myocardium and remained viable
(Fig. 4 and Additional file 2: Figure S2). Moreover,
transplantation of SIS-ECM-CPCs decreased the area
of myocardial scarring in mice with MI. The results of
real-time PCR showed that implantation of SIS-ECM
seeded with CPC-derived CMs decreased the expres-
sion levels of fibrosis related genes such as TGF-β,
Collagen I, and Collagen III. At 4 weeks after perman-
ent ligation, the occurrence of heart failure was con-
firmed by echocardiography. Transplantation of SIS-
ECM-CPCs improved LVEF and LVFS and decreased
LVEDD and LVESD at 4 weeks post implantation. In
addition, we demonstrated that the transplantation of
SIS-ECM-CPC patches did not affect the function of
normal hearts (Fig. 5). These data suggested that the
patch transplantation method used in this study was
safe.
To further determine the therapeutic effect of SIS-
ECM-CPC transplantation, we examined the expression
of heart failure markers associated with LV systolic dys-
function (Fig. 6). The results of real-time PCR showed
that LV myocardial expression of BNP and ANP mRNA
was significantly elevated in mice with MI compared
with sham mice at 4 weeks after permanent ligation of
the LAD. In addition, LV myocardial expression of
BNP mRNA was significantly lower in mice from the
MI + Patch group than in untreated mice with MI.
These data suggested that the transplantation of SIS-
ECM-CPCs was able to inhibit heart failure and im-
prove cardiac function induced by MI. However, the
effect of transplantation of SIS-ECM-CPC patches on
arrhythmia after MI was not investigated in this study,
and will need to be assessed in large animals in the
future.
The therapeutic effect of the SIS-ECM-CPC patch is
likely due to a combination of several mechanisms. A
patch can provide regional mechanical support after
transplantation [41, 42]. In addition, spontaneous
beating of the patch could be an advantage, which
could increase contractility like a small LV assist de-
vice [43]. In contrast, patches lacking spontaneous
contraction could be a burden to the host heart.
Furthermore, stem cell transplantation can attenuate
inflammatory response, inhibit fibrosis and stimulate cell
proliferation through a paracrine effect [44–47]. The
observed decrease of gene expression involved in fibrosis
and heart failure (Fig. 6) is consistent with this notion.
Future studies will reveal the details of these possible
mechanisms, including how the beating rate and rhythm
of SIS-ECM-CPC can be coordinated with the host beat-
ing rhythm initiated by the sinoatrial node.
Conclusion
Our studies demonstrated that transplantation of small
intestinal submucosa seeded with Isl1+ cardiac progeni-
tor cells significantly alleviated myocardial damage and
improved cardiac function following myocardial infarc-
tion in mice.
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Additional files
Additional file 1: Figure S1. Showing the proliferation rate of Isl1+ cells
by staining with mitotic marker ki67. (TIF 862 kb)
Additional file 2: Figure S2. Showing detection of Isl1+ CPC-derived
cell viability in SIS-ECM patches 28 days after transplantation. Frozen
sections of mouse hearts subjected to myocardial infarction and
transplantation of SIS-ECM-CPC patches before (A–C) and after fixation
by 4% paraformaldehyde (D) obtained by bright-field (A) and fluorescence
microscopy (B–D). (TIF 6084 kb)
Abbreviations
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